

## Disclosures

### Personal Commercial (9)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Abbott Laboratories	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Actelion	Speaker's Bureau	Significant (>= \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>
Akcea	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Astra Zeneca	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Bayer Healthcare Pharmaceuticals	Speaker's Bureau	Significant (>= \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>
Boehringer Ingelheim Pharmaceuticals, Inc	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Noninvasive Imaging</a>
Edwards Lifescience	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a> <a href="#">Valvular Heart Disease</a>
Pfizer Inc	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (8)

Trial Name	Trial Sponsor	Trial Funding Source
Intellect HF	Abbott Laboratories	
Prevent II	Abbott Laboratories	
SERENADE	Actelion	
HFN-LIFE	DCRI / Novartis	
VICTORIA	Merck & Co., Inc.	
PIONEER-HF	Novartis Corporation	
Relax-HF	Novartis Corporation	
Momentum III	Thoratec	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/31/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/31/2019

**Embargo** | Signed on 10/31/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 10/31/2019

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.